P1638: EARLY USE OF ELTROMBOPAG IN ADULT PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE CORTICOSTEROID THERAPY – AN AD HOC ANALYSIS OF THE TAPER TRIAL RESULTS

Ítems similars

• P1638: EARLY USE OF ELTROMBOPAG IN ADULT PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE CORTICOSTEROID THERAPY – AN AD HOC ANALYSIS OF THE TAPER TRIAL RESULTS
  per: W. Ghanima, et al.
  Publicat: (2022-06-01)
• PB2625: VAYHIT2: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO FAILED FIRST-LINE STEROID TREATMENT
  per: Francesco Zaja, et al.
  Publicat: (2023-08-01)
• PB2311: LOW-DOSE PREDNISON AND ELTROMBOPAG COMBINATION AS FRONTLINE TREATMENT IN NEWLY DIAGNOSED ITP PATIENTS
  per: S.-Y. Liu, et al.
  Publicat: (2022-06-01)
• Use and Effects of Eltrombopag in Pregnant Woman With Difficult-to-Treat Idiopathic Thrombocytopenic Purpura (ITP)
  per: Graciella Calsolari Figueiredo de Farias, et al.
  Publicat: (2025-01-01)
• P1589: PATIENT (PT) AND PHYSICIAN (MD) PERCEPTIONS OF THE BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) AND ITS MANAGEMENT: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) 2.0
  per: Nichola Cooper, et al.
  Publicat: (2023-08-01)